Global Liposomal Doxorubicin Market to Grow at a CAGR of 6.1% During 2022-2027, Driven by the Rising Health Issues Among Consumers

The rising approval of generic liposomal doxorubicin products by regulatory agencies is likely to raise demand for the drug, driving the growth of the market. Owing to its physicochemical features, which allow for high drug entrapment and facile remote loading in pre-formulated liposomes, doxorubicin is the most widely used chemotherapeutic agent in the market. The market growth can be associated with robust research and development (R&D) for evaluating various liposomal applications. Doxil®, pegylated liposomal doxorubicin that has been clinically approved and is available on the market, exhibits the benefits of liposome surface modification with polyethylene glycol. Thus, these are some of the factors contributing to the growth of the market.

In 2020, Zydus Cadila (NSE: CADILAHC), a significant player in the global market for liposomal doxorubicin, gained FDA clearance to market doxorubicin hydrochloride liposome injectable (US RLD: Doxil) single-dose vials in the strengths of 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL). Dr. Reddy's Laboratories Ltd (NYSE: RDY) stated in March 2017 that it had gained FDA permission to market doxorubicin hydrochloride liposome injection in the United States, which is a generic version of Janssen Products' Doxil (doxorubicin hydrochloride liposome injection). Doxorubicin hydrochloride liposome injection is used to treat ovarian cancer patients and is delivered intravenously. Such developments are likely to continue aiding the market in the forecast period.

Market Analysis by Product, Application, and Region:

• The market on the basis of product can be divided into Doxil/caelyx, lipodox, and myocet, among others.
• Based on its applications, the industry can be divided into leukaemia, bone sarcoma, breast cancer, endometrial cancer, gastric cancer, liver cancer, kidney cancer, multiple myeloma, and ovarian cancer, among other cancers.
• The regional markets for the market include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Key Findings of the Report:

• Doxorubicin is the most widely used chemotherapeutic agent to treat various types of cancers, which is a primary factor boosting market growth. 
• Approval of generic liposomal doxorubicin products by regulatory agencies is contributing to the growth of the market.
• Robust investments in research and development (R&D) aimed at evaluating the potential benefits of the drug are boosting the growth of the market. 
• The market for liposomal doxorubicin is also being augmented by several governmental aids like subsidies and payback schemes promoting the adoption of the drug for treatment purposes.

Key Offerings of the Report:

• The EMR report gives an overview of the liposomal doxorubicin industry for the periods (2017-2021) and (2022-2027).
• The report also offers the historical (2017-2021) and forecast (2022-2027) markets for the products, applications, and regions of the global liposomal doxorubicin market
• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with an assessment of the SWOT and Porter’s Five Forces models.

The major players in the global market for global liposomal doxorubicin are Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Cipla, Inc., Teva Pharmaceuticals Industries Ltd., and Janssen Products, LP, among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium-sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.